<DOC>
	<DOCNO>NCT02080871</DOCNO>
	<brief_summary>Evaluation Gore ( R ) VIABAHN BX treatment arterial occlusive disease common and/or external iliac artery .</brief_summary>
	<brief_title>A Study Gore VIABAHN BX Treatment Occlusive Disease Iliac Arteries .</brief_title>
	<detailed_description>This study prospective , multicenter , non-randomized single-arm clinical study evaluate safety efficacy VIABAHN BX treatment arterial occlusive disease patient de novo restenotic lesion common and/or external iliac artery .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Patient least 18 year old ; 2 . Patient male , infertile female , female childbearing potential practicing acceptable method prevent pregnancy ; 3 . Patient legal representative willing give write informed consent ; 4 . Patient capable comply protocol requirement , include followup visit ; 5 . Patient symptomatic claudication rest pain without tissue loss ( Rutherford Categories 24 ) . 6 . Patient de novo restenotic target lesion ( ) common and/or external iliac artery ; 7 . Patient one region stenosis ≥ 50 % target vessel , base visual estimate ; 8 . Patient target vessel diameter visually estimate approximately 5 mm 13 mm ; 9 . Patient adequate ipsilateral blood flow include least one sufficient ( &lt; 50 % stenotic ) infrapopliteal runoff vessel require intervention ( per side intervene ) . 10 . Patient total target lesion length visually estimate ≤110 mm treat maximum three VIABAHN BX endoprostheses ; 11 . Patient two discrete ipsilateral lesion treat three VIABAHN BX endoprostheses [ OR ] Patient bilateral disease consist one target lesion per side treat total three VIABAHN BX endoprostheses ; 12 . Patient device advance across target lesion ( ) position deployment . 1 . Patient life expectancy le 1 year ; 2 . Patient know allergy stent graft component , include stainless steel heparin ; 3 . Patient known intolerance antiplatelet , anticoagulant , thrombolytic medication would prevent compliance protocol ; 4 . Patient condition ( unrelated study ) expect require indefinite , lifelong , anticoagulation 5 . Patient uncorrected bleed disorder ( platelet count &lt; 80,000/µL ) ; 6 . Patient severe chronic renal insufficiency ( serum creatinine level &gt; 2.5mg/dL ) hemodialysis ; 7 . Patient known hypercoagulability correct ; 8 . Patient evidence blood borne infection ; 9 . Patient vascular access/catheterization lower extremity within 30 day study enrollment ; 10 . Patient previous plan coronary intervention within 30 day prior enrollment study require time study procedure ; 11 . Patient previous plan bypass surgery target leg , bypass occurs time index procedure ; 12 . Patient currently participate another investigative clinical study . 13 . Patient stent stent graft locate within immediately adjacent ( ≤5mm ) study lesion ( ) ; 14 . Patient evidence angiographically visible thrombus within adjacent target lesion ( ) ; 15 . Patient aneurysmal dilation proximal distal target lesion ( ) would interfere placement device ; 16 . Patient target lesion require atherectomy ablative device facilitate stent delivery ; 17 . Patient target lesion situate way implanted device prevent blood flow perfusion internal iliac artery patent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PAD</keyword>
	<keyword>Stent</keyword>
	<keyword>Claudication</keyword>
	<keyword>Viabahn</keyword>
	<keyword>Gore</keyword>
	<keyword>Endoprosthesis</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Iliac Occlusive Disease</keyword>
	<keyword>Balloon Expandable</keyword>
	<keyword>Stent-graft</keyword>
	<keyword>VBX</keyword>
</DOC>